The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop mucosal vaccines, including an influenza vaccine candidate. The collaboration ...

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others. Prasinezumab was originally ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

New Alzheimer’s drug tackles early disease progression.

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US. Ryoncil (remestemcel-L-rknd) has been granted approval by the FDA for ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US.

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases. GSK and ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US.